DeepMed Research

Corcept Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 352

Market Cap: $3.6B

Website

Clinical Trials

Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

Phase 4

Completed

Conditions: Hypercortisolism
Diabetes Mellitus, Type 2

Interventions: Drug: Mifepristone 300 MG [Korlym]
Drug: Placebo for mifepristone

First Posted Date: 2023-03-16

Last Posted Date: 2025-01-20

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 1113

Registration Number: NCT05772169

Locations: 🇺🇸
Site 407, Escondido, California, United States
🇺🇸
Site 379, Gardena, California, United States
🇺🇸
Site 378, Huntington Park, California, United States

and more 33 locations

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Phase 1

Completed

Conditions: Non-alcoholic Steatohepatitis (NASH)
Antipsychotic Induced Weight Gain

Interventions: Drug: Miricorilant
Drug: Fluvoxamine

First Posted Date: 2023-02-03

Last Posted Date: 2023-03-22

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 26

Registration Number: NCT05712265

Locations: 🇺🇸
Site 01, Miami, Florida, United States

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

Phase 1

Completed

Conditions: Non-alcoholic Steatohepatitis (NASH)

Interventions: Drug: Miricorilant

First Posted Date: 2022-09-23

Last Posted Date: 2025-03-30

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 19

Registration Number: NCT05553470

Locations: 🇺🇸
Site 03, Rialto, California, United States
🇺🇸
Site 02, Miami Lakes, Florida, United States
🇺🇸
Site 01, Miami, Florida, United States

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

Phase 2

Active, not recruiting

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Dazucorilant 150 mg
Drug: Dazucorilant 300 mg
Other: Placebo

First Posted Date: 2022-06-07

Last Posted Date: 2025-03-11

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 249

Registration Number: NCT05407324

Locations: 🇨🇦
425, Hamilton, Ontario, Canada
🇫🇷
261, Marseille, France
🇧🇪
108, Leuven, Belgium

and more 32 locations

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Phase 1

Completed

Conditions: Cushing Syndrome
Neoplasms

Interventions: Drug: Dabigatran Etexilate
Drug: Relacorilant

First Posted Date: 2022-04-27

Last Posted Date: 2023-02-09

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 30

Registration Number: NCT05347979

Locations: 🇺🇸
Site 01, Miami, Florida, United States

A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Completed

Conditions: Nonalcoholic Steatohepatitis (NASH)

Interventions: Other: MRI-PDFF

First Posted Date: 2022-04-11

Last Posted Date: 2024-08-19

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 22

Registration Number: NCT05320146

Locations: 🇺🇸
Site 233, Santa Ana, California, United States
🇺🇸
226, Seattle, Washington, United States
🇺🇸
305, Houston, Texas, United States

and more 6 locations

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Phase 3

Active, not recruiting

Conditions: Ovarian Neoplasm
Fallopian Tube Neoplasms
Peritoneal Neoplasms

Interventions: Drug: Nab-paclitaxel 80 mg/m^2
Drug: Nab-paclitaxel 100 mg/m^2
Drug: Relacorilant 150 mg once daily (QD)

First Posted Date: 2022-02-25

Last Posted Date: 2025-04-16

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 381

Registration Number: NCT05257408

Locations: 🇺🇸
Site 272, Atlanta, Georgia, United States
🇺🇸
Site 339, Indianapolis, Indiana, United States
🇺🇸
Site 127, Pittsburgh, Pennsylvania, United States

and more 113 locations

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Phase 1

Completed

Conditions: Nonalcoholic Steatohepatitis (NASH)

Interventions: Drug: Miricorilant 100 mg
Drug: Miricorilant 150 mg
Drug: Miricorilant 50 mg
Drug: Miricorilant 10 mg

First Posted Date: 2021-11-11

Last Posted Date: 2024-08-19

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 70

Registration Number: NCT05117489

Locations: 🇺🇸
Site 207, Chandler, Arizona, United States
🇺🇸
Site 214, Panorama City, California, United States
🇺🇸
Site 211, Austin, Texas, United States

and more 6 locations

Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo matching CORT125236
Drug: CORT125236
Drug: Prednisone

First Posted Date: 2021-08-12

Last Posted Date: 2023-03-22

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 82

Registration Number: NCT05003713

Locations: 🇬🇧
Site 01, Ruddington, Nottingham, United Kingdom

Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Adults

Interventions: Drug: Placebo matching CORT113176
Drug: CORT113176

First Posted Date: 2021-08-06

Last Posted Date: 2021-10-11

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 16

Registration Number: NCT04994743

Locations: 🇳🇱
Site 01, Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy